|
| (Ref.) |
|
| Antimitogenic (particularly towards PA-SMCs) | |
| PDGF inhibitors | [4] |
| Endothelin receptor blockers | [16–19, 29] |
| Prostacyclin (analogue) | [5–10, 15, 19] |
| Serotonin transporter inhibitors | [21] |
| Serotonin receptor blockers | [23, 24] |
| Serotonic re-uptake inhibitor | [22] |
| PDE 4/5 and 3/4 inhibitors | [9, 10, 25–29] |
| Caveolin-1 peptide | [30] |
| Estradiol (derivatives) | [31–34] |
| Amlodipine | [38] |
| Rapamycin | [42] |
| Cell therapy using differentiated cells transduced with eNOS gene | [60, 62, 63, 68] |
| Prostacyclin synthase gene | [55, 56] |
| NF-κB inhibitor | [44] |
| Serine-elastase inhibitors | [3] |
| Proendothelial function, vasodilatation, and proangiogenesis | |
| Rho-kinase inhibitors | [11–15] |
| Statins | [35–37] |
| Nicorandil | [39] |
| Granulocyte-colony stimulating factor | [43] |
| L-arginine | [50] |
| Prostacyclin (analogue) | [5–10, 15, 19] |
| Endothelin receptor blockers | [16–19, 29] |
| PDE 4/5 and 3/4 inhibitors | [9, 10, 25–29] |
| Adrenomedullin | [41] |
| Prostacyclin synthase gene | [55, 56] |
| Angiopoietin-1 gene | [57] |
| Cell therapy using EPCs and MSCs | [59, 63–65, 68–71] |
| Cell therapy using differentiated cells transduced with eNOS gene | [60, 62, 63, 68] |
| Cell therapy using differentiated cells transduced with VEGF gene | [61, 62] |
| Anti-inflammatory and antioxidative | |
| Serotonin receptor blockers | [23, 24] |
| Amlodipine | [38] |
| Nicorandil | [39] |
| Statins | [35–37] |
| C-type natriuretic factor | [40] |
| Interleukin-1 receptor antagonist | [45] |
| Antibodies to monocyte chemotactic and activating factor/MCP1 | [46] |
| Inhibitor of p38 mitogen-activated protein kinase | [47] |
| Inhibitor of lipoxygenase pathways | [51] |
| Antimonocyte chemoattractant protein-1 gene | [54] |
| Interleukin-10 gene | [58] |
| Extracellular superoxide dismutase gene | [53] |
|
